Patent intelligence · US
US 9782345
Ocular composition and method
Ocular composition and method
Patent details — US 9782345
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 10, 2017
- Expiration
- Oct 5, 2037
- Applicant
- Jade Therapeutics, Inc.
- Claims
- 24
- CPC classes
- A61K, A61K31/407, A61K31/4709, A61K31/522
Quick answer
US 9782345 (Ocular composition and method) is held by Jade Therapeutics, Inc.. Status: granted. Granted Oct 10, 2017. Expires Oct 5, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Jade Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 24
- CPC classes
- A61K, A61K31/407, A61K31/4709, A61K31/522, A61K31/5575, A61K31/7036
More from Jade Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 9782345?
US 9782345 (Ocular composition and method) is held by Jade Therapeutics, Inc.. Status: granted. Granted Oct 10, 2017. Expires Oct 5, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9782345?
Jade Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 2 pharmaceutical patents for this assignee.
When does US 9782345 expire?
Our index shows an expiration date of Oct 5, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.